Omaxe attractively priced, may see Rs 450 on listing

Published on Fri, Jul 20, 2007 at 12:58 |  Source : Moneycontrol.com

Updated at Fri, Jul 20, 2007 at 13:04  

Like this story, share it with millions of investors on M3
0
0
Share on Tumblr

Excerpts from Bazaar on CNBC-TV18 Watch the full show ยป

ALSO READ

Q: There will be some interesting figures to talk about by the end of the day on Omaxe?

A: There should be because it seems attractively price for a real estate IPO. I do not remember as far back but I remember till Parsvnath and Akruti Nirman, the last gush of issues, which came. But I cannot think of too many issues, which came with such a big discount to NAV specially good quality paper. Omaxe is not bad quality paper at all; it's a large company, large issue. It's fairly dominant player in the northern part of the country, present in all the markets and most people believe that the NAV works out between Rs 400-450 per share for Omaxe at the higher end, you are getting the stock at Rs 300-310.

Potentially there is a 50% kind of appreciation on listing for you; it depends on whole host of other things but can Omaxe get to one time NAV in a context of how other real estate stocks are trading; I think it's entirely possible. So buy at Rs 310 if you are lucky to get some allotment you could possibly see Rs 450 on listing as much as that. I do not think too many real estate IPOs left that much on the table in recent times. So I think you will see very good subscription, you are already seeing quite a bit of subscription before the last day and there will be more to come today and I think people will make money on Omaxe. 

  

Trending News

Business News

Tim Cook speaks candidly about Apple at D10
Did Sebi miss any tricks in Ambani consent order? "Did Sebi miss any tricks in Ambani consent order?"

Oppn gears up to make Bharat bandh a success

On Facebook IPO Morgan Stanley Speculation Of 'Nefarious Activity' Around IPO Untrue

The latest earning numbers FIRST on CNBC-TV18
Videos

May 30 2012, 23:16

Clash of Spain and ECB worrying investors: Verstrate

- in FII View

May 30 2012, 11:18

Result corner: Ajay Bodke`s top bets from across sectors

- in MARKET OUTLOOK

Interviews

May 30 2012, 17:04 | Source: CNBC-TV18

Margins may be hit on one-off items in EBITDA: Sun Pharma  

May 30 2012, 16:32 | Source: CNBC-TV18

Essar announces Rs 175cr deal; to pay-off debts with fund  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!